# A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06589778/  
OnCo record `nct06589778` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-A2102, Adebrelimab, SHR-8068 in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06589778 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 124 participants planned, started 2024-09-27 and due to reach its primary completion in 2026-04-30. Interventions recorded: SHR-A2102, Adebelimab (SHR-1316), SHR-8068. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06589778
- Phase: 1/2
- Setting: Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB/II Open-Label, Multicenter Clinical Study
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 124

## Sources

- ClinicalTrials.gov NCT06589778: https://clinicaltrials.gov/study/NCT06589778

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06589778.json